Advertisement

Paraneoplastic Neuromuscular Disorders

  • Betul Gundogdu
  • Myrna R. Rosenfeld
  • Stacy A. Rudnicki
Chapter

Abstract

Paraneoplastic neurologic and neuromuscular disorders are usually immune mediated and often associated with specific anti-neuronal antibodies. This chapter will focus on those paraneoplastic disorders that predominantly produce neuromuscular dysfunction and which are likely to be encountered in clinical practice.

Keywords

Paraneoplastic neurologic disorders sensory neuronopathy Lambert-Eaton myasthenic syndrome acute necrotizing myelopathy Anti-Hu antibody myokymia neuromyotonia stiff-person syndrome myeloma Waldetrom’s 

References

  1. 1.
    Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135–40.PubMedCrossRefGoogle Scholar
  2. 2.
    Vernino S, O’Neill BP, Marks RS, O’Fallon JR, Kimmel DW. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol. 2004;6:55–62.PubMedCrossRefGoogle Scholar
  3. 3.
    Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore). 1992;71:59–72.Google Scholar
  4. 4.
    Oki Y, Koike H, Iijima M, et al. Ataxic vs painful form of paraneoplastic neuropathy. Neurology. 2007;69:564–72.PubMedCrossRefGoogle Scholar
  5. 5.
    Kuntzer T, Antoine JC, Steck AJ. Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies). Muscle Nerve. 2004;30:255–68.PubMedCrossRefGoogle Scholar
  6. 6.
    Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated ­paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124:1138–48.PubMedCrossRefGoogle Scholar
  7. 7.
    Eggers C, Hagel C, Pfeiffer G. Anti-Hu-associated paraneoplastic sensory neuropathy with peripheral nerve demyelination and ­microvasculitis. J Neurol Sci. 1998;155:178–81.PubMedCrossRefGoogle Scholar
  8. 8.
    Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological ­symptoms, immunological findings, and tumor association in 50 patients. Brain. 2000;123:1481–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Fujimoto S, Kumamoto T, Ito T, Sannomiya K, Inuzuka T, Tsuda T. A clinicopathological study of a patient with anti-Hu-associated paraneoplastic sensory neuronopathy with multiple cranial nerve palsies. Clin Neurol Neurosurg. 2002;104:98–102.PubMedCrossRefGoogle Scholar
  10. 10.
    Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and ­oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology. 1998;50:652–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Llado A, Carpentier AF, Honnorat J, et al. Hu-antibody-positive patients with or without cancer have similar clinical profiles. J Neurol Neurosurg Psychiatry. 2006;77:996–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Honnorat J, Cartalat-Carel S, Ricard D, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry. 2009;80:412–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Yu Z, Kryzer TJ, Griesmann GE, Kim KK, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma related autoimmunity. Ann Neurol. 2001;49:146–54.PubMedCrossRefGoogle Scholar
  14. 14.
    Camdessanche JP, Antoine JC, Honnorat J, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain. 2002;125:166–75.PubMedCrossRefGoogle Scholar
  15. 15.
    Oh SJ, Gurtekin Y, Dropcho EJ, King P, Claussen GC. Anti-Hu antibody neuropathy: a clinical, electrophysiological, and pathological study. Clin Neurophysiol. 2005;116:28–34.PubMedCrossRefGoogle Scholar
  16. 16.
    Sillevis SP, Grefkens J, De Leeuw B, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol. 2002;249:745–53.CrossRefGoogle Scholar
  17. 17.
    Camdessanche JP, Jousserand G, Ferraud K, et al. The pattern and diagnostic criteria of sensory neuronopathy: a case–control study. Brain. 2009;132:1723–33.PubMedCrossRefGoogle Scholar
  18. 18.
    Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006;24:1633–42.PubMedCrossRefGoogle Scholar
  19. 19.
    Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve. 2005;32:51–60.PubMedCrossRefGoogle Scholar
  20. 20.
    Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology. 2007;69:573–81.PubMedCrossRefGoogle Scholar
  21. 21.
    Willison HJ, O’Leary CP, Veitch J, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain. 2001;124:1968–77.PubMedCrossRefGoogle Scholar
  22. 22.
    Sanvito L, Rajabally YA. Optic neuropathy associated with CANOMAD: description of 2 cases. Muscle Nerve. 2011;44:451–5.PubMedGoogle Scholar
  23. 23.
    Chio A, Brignolio F, Meineri P, Rosso MG, Tribolo A, Schiffer D. Motor neuron disease and malignancies: results of a population-based study. J Neurol. 1988;235:374–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Kurtzke JF, Beebe GW. Epidemiology of amyotrophic lateral sclerosis: 1. A case–control comparison based on ALS deaths. Neurology. 1980;30:453–62.PubMedCrossRefGoogle Scholar
  25. 25.
    Chio A, Calvo A, Moglia C, et al. May ALS phenotype be considered a part of the disease spectrum of paraneoplastic diseases? Amyotroph Lateral Scler. 2011;12 suppl 1:24.Google Scholar
  26. 26.
    Evans BK, Fagan C, Arnold T, Dropcho EJ, Oh SJ. Paraneoplastic motor neuron disease and renal cell carcinoma: improvement after nephrectomy. Neurology. 1990;40:960–2.PubMedCrossRefGoogle Scholar
  27. 27.
    Forman D, Rae-Grant AD, Matchett SC, Cowen JS. A reversible cause of hypercapnic respiratory failure: lower motor neuronopathy associated with renal cell carcinoma. Chest. 1999;115:899–901.PubMedCrossRefGoogle Scholar
  28. 28.
    Ferracci F, Fassetta G, Butler MH, Floyd S, Solimena M, De Camilli P. A novel antineuronal antibody in a motor neuron syndrome associated with breast cancer. Neurology. 1999;53:852–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Forsyth PA, Dalmau J, Graus F, Cwik V, Rosenblum MK, Posner JB. Motor neuron syndromes in cancer patients. Ann Neurol. 1997;41:722–30.PubMedCrossRefGoogle Scholar
  30. 30.
    Carnevale V, Minisola S, Romagnoli E, et al. Concurrent improvement of neuromuscular and skeletal involvement following surgery for primary hyperparathyroidism. J Neurol. 1992;239:57.PubMedCrossRefGoogle Scholar
  31. 31.
    Thomas P, Lebrun C. Progressive spastic paraparesis revealing ­primary hyperparathyroidism. Neurology. 1994;44:178–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Jackson CE, Amato AA, Bryan WW, Wolfe GI, Sakhaee K, Barohn RJ. Primary hyperparathyroidism and ALS: is there a relation? Neurology. 1998;50:1795–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Rison RA, Beydoun SR. Amyotrophic lateral sclerosis-motor ­neuron disease, monoclonal gammopathy, hyperparathyroidism, and B12 deficiency: case report and review of the literature. J Med Case Reports. 2010;4:298.CrossRefGoogle Scholar
  34. 34.
    Carvalho AA, Vieira A, Simplicio H, Fugygara S, Carvalho SM, Rigueiro MP. Primary hyperparathyroidism simulating motor ­neuron disease: case report. Arq Neuropsiquiatr. 2005;63:160–2.PubMedCrossRefGoogle Scholar
  35. 35.
    Barker RA, Revesz T, Thom M, Marsden CD, Brown P. Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry. 1998;65:633–40.PubMedCrossRefGoogle Scholar
  36. 36.
    Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131:2553–63.PubMedCrossRefGoogle Scholar
  37. 37.
    Agarwal PA, Ichaporia NR. Glutamic acid decarboxylase antibody-positive paraneoplastic stiff limb syndrome associated with carcinoma of the breast. Neurol India. 2010;58:449–51.PubMedCrossRefGoogle Scholar
  38. 38.
    Schiff D, Dalmau J, Myers DJ. Anti-GAD antibody positive ­stiff-limb syndrome in multiple myeloma. J Neurooncol. 2003;65:173–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Hagiwara H, Enomoto-Nakatani S, Sakai K, Ugawa Y, Kusunoki S, Kanazawa I. Stiff-person syndrome associated with invasive ­thymoma: a case report. J Neurol Sci. 2001;193:59–62.PubMedCrossRefGoogle Scholar
  40. 40.
    Pittock SJ, Lucchinetti CF, Parisi JE, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005;58:96–107.PubMedCrossRefGoogle Scholar
  41. 41.
    Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology. 2008;71:1955–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Ruegg SJ, Steck AJ, Fuhr P. Levetiracetam improves paroxysmal symptoms in a patient with stiff-person syndrome. Neurology. 2004;62:338.PubMedCrossRefGoogle Scholar
  43. 43.
    Holmoy T. Long-term effect of gabapentin in stiff limb syndrome: a case report. Eur Neurol. 2007;58:251–2.PubMedCrossRefGoogle Scholar
  44. 44.
    Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. ­High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 2001;345:1870–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Schmierer K, Valdueza JM, Bender A, et al. Atypical stiff-person syndrome with spinal MRI findings, amphiphysin autoantibodies, and immunosuppression. Neurology. 1998;51:250–2.PubMedCrossRefGoogle Scholar
  46. 46.
    Flanagan EP, McKeon A, Lennon VA, et al. Paraneoplastic isolated myelopathy: clinical course and neuroimaging Clues. Neurology. 2011;76:2089–95.PubMedCrossRefGoogle Scholar
  47. 47.
    Julien J, Vital C, Aupy G, Lagueny A, Darriet D, Brechenmacher C. Guillain-Barre syndrome and Hodgkin’s disease. Ultrastructural study of a peripheral nerve. J Neurol Sci. 1980;45:23–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Vigliani MC, Magistrello M, Polo P, Mutani R, Chio A. Risk of cancer in patients with Guillain-Barre syndrome (GBS). A population-based study. J Neurol. 2004;251:321–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Nokura K, Nagamatsu M, Inagaki T, et al. Acute motor and sensory neuronopathy associated with small-cell lung cancer: a clinicopathological study. Neuropathology. 2006;26:329–37.PubMedCrossRefGoogle Scholar
  50. 50.
    Croft PB, Urich H, Wilkinson M. Peripheral neuropathy of sensorimotor type associated with malignant disease. Brain. 1967;90:31–66.PubMedCrossRefGoogle Scholar
  51. 51.
    Samarasekera S, Rajabally YA. Demyelinating neuropathy with anti-CRMP5 antibodies predating diagnosis of breast carcinoma: favorable outcome after cancer therapy. Muscle Nerve. 2011;43:764–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton III LJ. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc. 2004;79:859–66.PubMedCrossRefGoogle Scholar
  53. 53.
    Rajabally YA. Neuropathy and paraproteins: review of a complex association. Eur J Neurol. 2011;18:1291–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Nobile-Orazio E, Manfredini E, Carpo M, et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol. 1994;36:416–24.PubMedCrossRefGoogle Scholar
  55. 55.
    Nobile-Orazio E, Hays AP, Latov N, et al. Specificity of mouse and human monoclonal antibodies to myelin-associated glycoprotein. Neurology. 1984;34:1336–42.PubMedCrossRefGoogle Scholar
  56. 56.
    Steck AJ, Stalder AK, Renaud S. Anti-myelin-associated glycoprotein neuropathy. Curr Opin Neurol. 2006;19:458–63.PubMedCrossRefGoogle Scholar
  57. 57.
    Steck AJ, Murray N, Dellagi K, Brouet JC, Seligmann M. Peripheral neuropathy associated with monoclonal IgM autoantibody. Ann Neurol. 1987;22:764–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Nobile-Orazio E, Meucci N, Baldini L, Di TA, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain. 2000;123:710–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Yeung KB, Thomas PK, King RH, et al. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. J Neurol. 1991;238:383–91.PubMedCrossRefGoogle Scholar
  60. 60.
    Larue S, Bombelli F, Viala K, et al. Non-anti-MAG DADS ­neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol. 2011;18:899–905.PubMedCrossRefGoogle Scholar
  61. 61.
    Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30:110–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Gertz MA. Waldenstrom macroglobulinemia: a review of therapy. Am J Hematol. 2005;79:147–57.PubMedCrossRefGoogle Scholar
  63. 63.
    Dimopoulos MA, Alexanian R. Waldenstrom’s macroglobulinemia. Blood. 1994;83:1452–9.PubMedGoogle Scholar
  64. 64.
    Levine T, Pestronk A, Florence J, et al. Peripheral neuropathies in Waldenstrom’s macroglobulinaemia. J Neurol Neurosurg Psychiatry. 2006;77:224–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis: diagnosis and management. Clin Lymphoma Myeloma. 2005;6:208–19.PubMedCrossRefGoogle Scholar
  66. 66.
    Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36:411–23.PubMedCrossRefGoogle Scholar
  67. 67.
    Kelly Jr JJ, Kyle RA, O’Brien PC, Dyck PJ. The natural history of peripheral neuropathy in primary systemic amyloidosis. Ann Neurol. 1979;6:1–7.PubMedCrossRefGoogle Scholar
  68. 68.
    Tracy JA, Dyck PJ, Dyck PJ. Primary amyloidosis presenting as upper limb multiple mononeuropathies. Muscle Nerve. 2010;41:710–5.PubMedCrossRefGoogle Scholar
  69. 69.
    Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Gertz MA, Lacy MQ, Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant. 2011;46:970–5.PubMedCrossRefGoogle Scholar
  71. 71.
    Sonneveld P, Jongen JL. Dealing with neuropathy in plasma-cell dyscrasias. Hematology Am Soc Hematol Educ Program. 2010;2010:423–30.PubMedCrossRefGoogle Scholar
  72. 72.
    Miralles GD, O’Fallon JR, Talley NJ. Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. N Engl J Med. 1992;327:1919–23.PubMedCrossRefGoogle Scholar
  73. 73.
    Sung JY, Kuwabara S, Ogawara K, Kanai K, Hattori T. Patterns of nerve conduction abnormalities in POEMS syndrome. Muscle Nerve. 2002;26:189–93.PubMedCrossRefGoogle Scholar
  74. 74.
    Vital C, Vital A, Ferrer X, et al. Crow-Fukase (POEMS) syndrome: a study of peripheral nerve biopsy in five new cases. J Peripher Nerv Syst. 2003;8:136–44.PubMedCrossRefGoogle Scholar
  75. 75.
    Kuwabara S, Dispenzieri A, Arimura K, Misawa S. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev. 2008;4:CD006828.Google Scholar
  76. 76.
    Castleman B, Towne VW. Case records of the Massachusetts General Hospital: case no. 40231. N Engl J Med. 1954;250:1001–5.PubMedCrossRefGoogle Scholar
  77. 77.
    Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated ­multicentric Castleman’s disease. Ann Oncol. 2009;20:775–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Donaghy M, Hall P, Gawler J, et al. Peripheral neuropathy associated with Castleman’s disease. J Neurol Sci. 1989;89:253–67.PubMedCrossRefGoogle Scholar
  79. 79.
    Zivkovic SA, Ascherman D, Lacomis D. Vasculitic neuropathy – electrodiagnostic findings and association with malignancies. Acta Neurol Scand. 2007;115:432–6.PubMedCrossRefGoogle Scholar
  80. 80.
    Johnson PC, Rolak LA, Hamilton RH, Laguna JF. Paraneoplastic vasculitis of nerve: a remote effect of cancer. Ann Neurol. 1979;5:437–44.PubMedCrossRefGoogle Scholar
  81. 81.
    Younger DS, Dalmau J, Inghirami G, Sherman WH, Hays AP. Anti-Hu-associated peripheral nerve and muscle microvasculitis. Neurology. 1994;44:181–3.PubMedCrossRefGoogle Scholar
  82. 82.
    Martin AC, Friedlander M, Kiernan MC. Paraneoplastic mononeuritis multiplex in non-small-cell lung carcinoma. J Clin Neurosci. 2006;13:595–8.PubMedCrossRefGoogle Scholar
  83. 83.
    Oh SJ, Slaughter R, Harrell L. Paraneoplastic vasculitic neuropathy: a treatable neuropathy. Muscle Nerve. 1991;14:152–6.PubMedCrossRefGoogle Scholar
  84. 84.
    Blumenthal D, Schochet Jr S, Gutmann L, Ellis B, Jaynes M, Dalmau J. Small-cell carcinoma of the lung presenting with paraneoplastic peripheral nerve microvasculitis and optic neuropathy. Muscle Nerve. 1998;21:1358–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Tahmoush AJ, Alonso RJ, Tahmoush GP, Heiman-Patterson TD. Cramp-fasciculation syndrome: a treatable hyperexcitable peripheral nerve disorder. Neurology. 1991;41:1021–4.PubMedCrossRefGoogle Scholar
  86. 86.
    Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain. 2002;125:1887–95.PubMedCrossRefGoogle Scholar
  87. 87.
    Isaacs H. A syndrome of continuous muscle-fibre activity. J Neurol Neurosurg Psychiatry. 1961;24:319–25.PubMedCrossRefGoogle Scholar
  88. 88.
    Morvan A. De la chorée fibrillaire. Gaz Hebd Mèd Chir. 1890;27:173–200.Google Scholar
  89. 89.
    Rubio-Agusti I, Perez-Miralles F, Sevilla T, et al. Peripheral nerve hyperexcitability: a clinical and immunologic study of 38 patients. Neurology. 2011;76:172–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Vernino S, Lennon VA. Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability. Muscle Nerve. 2002;26:702–7.PubMedCrossRefGoogle Scholar
  91. 91.
    Lancaster E, Huijbers MG, Bar V, et al. Investigations of Caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol. 2011;69:303–11.PubMedCrossRefGoogle Scholar
  92. 92.
    Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain. 2010;133:2734–48.PubMedCrossRefGoogle Scholar
  93. 93.
    Maddison P, Mills KR, Newsom-Davis J. Clinical electrophysiological characterization of the acquired neuromyotonia phenotype of autoimmune peripheral nerve hyperexcitability. Muscle Nerve. 2006;33:801–8.PubMedCrossRefGoogle Scholar
  94. 94.
    Lee EK, Maselli RA, Ellis WG, Agius MA. Morvan’s fibrillary chorea: a paraneoplastic manifestation of thymoma. J Neurol Neurosurg Psychiatry. 1998;65:857–62.PubMedCrossRefGoogle Scholar
  95. 95.
    Bednarlk J, Kadanka Z. Volitional and stimulation induced neuromyotonic discharges: unusual electrophysiological pattern in acquired neuromyotonia. J Neurol Neurosurg Psychiatry. 2001;70:406–7.PubMedCrossRefGoogle Scholar
  96. 96.
    Humphrey JG, Hill ME, Gordon AS, Kalow W. Myotonia associated with small cell carcinoma of the lung. Arch Neurol. 1976;33:375–6.PubMedCrossRefGoogle Scholar
  97. 97.
    Sanders DB, Massey JM. Clinical features of myasthenia gravis. Handb Clin Neurol. 2008;91:229–52.PubMedCrossRefGoogle Scholar
  98. 98.
    Husain AM, Massey JM, Howard JF, Sanders DB. Acetylcholine receptor antibody measurements in acquired myasthenia gravis. Diagnostic sensitivity and predictive value for thymoma. Ann N Y Acad Sci. 1998;841:471–4.PubMedCrossRefGoogle Scholar
  99. 99.
    Howard Jr JF, Sanders DB, Massey JM. The electrodiagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Neurol Clin. 1994;12:305–30.PubMedGoogle Scholar
  100. 100.
    Meriggioli MN, Sanders DB. Myasthenia gravis: diagnosis. Semin Neurol. 2004;24:31–9.PubMedCrossRefGoogle Scholar
  101. 101.
    Bril V, Kojic J, Dhanani A. The long-term clinical outcome of myasthenia gravis in patients with thymoma. Neurology. 1998;51:1198–200.PubMedCrossRefGoogle Scholar
  102. 102.
    Tormoehlen LM, Pascuzzi RM. Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am. 2008;22:509–26.PubMedCrossRefGoogle Scholar
  103. 103.
    Maggi L, Andreetta F, Antozzi C, et al. Thymoma-associated myasthenia gravis: outcome, clinical and pathological correlations in 197 patients on a 20-year experience. J Neuroimmunol. 2008;201–202:237–44.PubMedCrossRefGoogle Scholar
  104. 104.
    Suzuki S, Utsugisawa K, Nagane Y, Suzuki N. Three types of striational antibodies in myasthenia gravis. Autoimmune Disord. 2011;2011:740583.Google Scholar
  105. 105.
    Romi F, Gilhus NE, Aarli JA. Myasthenia gravis: clinical, immunological, and therapeutic advances. Acta Neurol Scand. 2005;111:134–41.PubMedCrossRefGoogle Scholar
  106. 106.
    Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44:36–40.PubMedCrossRefGoogle Scholar
  107. 107.
    Zahid I, Sharif S, Routledge T, Scarci M. Video-assisted ­thoracoscopic surgery or transsternal thymectomy in the treatment of myasthenia gravis? Interact Cardiovasc Thorac Surg. 2011;12:40–6.PubMedCrossRefGoogle Scholar
  108. 108.
    Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116:2843–54.PubMedCrossRefGoogle Scholar
  109. 109.
    Maggi L, Mantegazza R. Treatment of myasthenia gravis: focus on pyridostigmine. Clin Drug Investig. 2011;31:691–701.PubMedCrossRefGoogle Scholar
  110. 110.
    O’Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988;111:577–96.PubMedCrossRefGoogle Scholar
  111. 111.
    Hatanaka Y, Oh SJ. Ten-second exercise is superior to 30-s exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2008;37:572–5.PubMedCrossRefGoogle Scholar
  112. 112.
    Titulaer MJ, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann N Y Acad Sci. 2008;1132:129–34.PubMedCrossRefGoogle Scholar
  113. 113.
    Argov Z, Shapira Y, Averbuch-Heller L, Wirguin I. Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders. Muscle Nerve. 1995;18:715–9.PubMedCrossRefGoogle Scholar
  114. 114.
    Morimoto M, Osaki T, Nagara Y, Kodate M, Motomura M, Murai H. Thymoma with Lambert-Eaton myasthenic syndrome. Ann Thorac Surg. 2010;89:2001–3.PubMedCrossRefGoogle Scholar
  115. 115.
    Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002;104:359–63.PubMedCrossRefGoogle Scholar
  116. 116.
    Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18:19-e3.PubMedCrossRefGoogle Scholar
  117. 117.
    Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332:1467–74.PubMedCrossRefGoogle Scholar
  118. 118.
    Motomura M, Lang B, Johnston I, Palace J, Vincent A, ­Newsom-Davis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton ­myasthenic syndrome. J Neurol Sci. 1997;147:35–42.PubMedCrossRefGoogle Scholar
  119. 119.
    Sabater L, Titulaer M, Saiz A, Verschuuren J, Gure AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert Eaton myasthenic syndrome. J Clin Oncol. 2007;27:4260–7.Google Scholar
  120. 120.
    Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29:902–8.PubMedCrossRefGoogle Scholar
  121. 121.
    Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2011;(2):CD003279.Google Scholar
  122. 122.
    Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic ­syndrome. Neurology. 2000;54:603–7.PubMedCrossRefGoogle Scholar
  123. 123.
    Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of 3,4-­diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther. 2009;86:44–8.PubMedCrossRefGoogle Scholar
  124. 124.
    Lindquist S, Stangel M. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat. 2011;7:341–9.PubMedGoogle Scholar
  125. 125.
    Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic ­syndrome. Neurology. 1984;34:480–5.PubMedCrossRefGoogle Scholar
  126. 126.
    Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50:1778–83.PubMedCrossRefGoogle Scholar
  127. 127.
    Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology. 2000;54:2176–8.PubMedCrossRefGoogle Scholar
  128. 128.
    Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996;47:678–83.PubMedCrossRefGoogle Scholar
  129. 129.
    Maddison P, McConville J, Farrugia ME, et al. The use of ­rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2011;82:671–3.PubMedCrossRefGoogle Scholar
  130. 130.
    Pellkofer HL, Voltz R, Kuempfel T. Favorable response to ­rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve. 2009;40:305–8.PubMedCrossRefGoogle Scholar
  131. 131.
    Hochberg MC, Feldman D, Stevens MB, Arnett FC, Reichlin M. Antibody to Jo-1 polymyositis/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol. 1984;11:663–5.PubMedGoogle Scholar
  132. 132.
    Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neurol. 1995;37:S74–5.PubMedCrossRefGoogle Scholar
  133. 133.
    Smith B. Skeletal muscle necrosis associated with cainoma. J Pathol. 1969;97:207–10.PubMedCrossRefGoogle Scholar
  134. 134.
    Bronner IM, Hoogendijk JE, Wintzen AR, et al. Necrotising ­myopathy, an unusual presentation of a steroid-responsive ­myopathy. J Neurol. 2003;250:480–5.PubMedCrossRefGoogle Scholar
  135. 135.
    Urich H, Wilkinson M. Necrosis of muscle with carcinoma: myositis or myopathy? J Neurol Neurosurg Psychiatry. 1970;33:398–407.PubMedCrossRefGoogle Scholar
  136. 136.
    Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology. 1998;50:764–7.PubMedCrossRefGoogle Scholar
  137. 137.
    Galani E, Bonakis A, Christodoulou C, Klouvas G, Drougou A, Skarlos D. Can cetuximab affect paraneoplastic myopathy? J Neurooncol. 2009;93:437–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Betul Gundogdu
    • 1
  • Myrna R. Rosenfeld
    • 2
  • Stacy A. Rudnicki
    • 1
  1. 1.Department of NeurologyUniversity of Arkansas for Medical SciencesLittle RockUSA
  2. 2.Department of NeurologyInstitute of Biomedical Investigations (IDIBAPS), Clinic HospitalBarcelonaSpain

Personalised recommendations